The Global 3D Bioprinting market is projected to grow at a CAGR of around 16% during the forecast period of 2023-28, cites MarkNtel Advisors in their recent research report. The major factor supporting the growing demand for this printing technique is the rising number of deaths of millions of rabbits, mice, primates, dogs, and other animals, used for animal testing. Despite the fact that these animals are unable to completely mimic the human tissue environment and immune response, their use in clinical drug and cosmetic testing is rising. This is where 3D bioprinting comes into play, as it allows the creation of replica models for respiratory, skin, ocular, oral, and intestinal tissue, providing a more physiologically relevant environment for drug testing.
Moreover, the growing number of deaths related to the shortage of organs for transplantation further generates the demand for 3D bioprinting, as it would allow the bioprinting of organs, which would help clinicians to keep up with patients. Additionally, the use of bio-printed tissues enables the treatment of patients who are suffering from diseases that need the replacement of damaged tissues in their early stages. Furthermore, the mounting need for this printing technique from a variety of applications, including bone bandages, plastic surgeries, skin grafts, and more, is boosted by the expanding availability of tissue-specific bioinks like neurons, hepatocytes, artificial skin cells, and others. Moreover, the statistics on cancer-related deaths around the world emphasize the need for researchers to prioritize finding cancer cures. In contrast to animal testing methods, 3D bioprinted tissues have an advantage in cancer research as they accurately mimic the human environment.
Furthermore, 3D printing provides an effective environment for the drug, allowing it to respond to external signals from surrounding cells. The relevant cell-to-cell interaction, which enables demonstrating oxygenation, drug & nutrient uptake, cell proliferation, morphology, excretion, etc., aids in the efficient study of cancer progression & drug screening over the same. As a result of rising demand from cancer research institutes & pharmaceutical companies working on cancer drug development, the market is expanding rapidly, further states the research report, "Global 3D Bioprinting Market Analysis, 2023."
With the Highest Demand from the Healthcare Industry, Inkjet Bioprinting Dominates Market
Based on technology, the market is bifurcated into Syringe/Extrusion Bioprinting, Inkjet Bioprinting, Magnetic Levitation Bioprinting, Laser-assisted Bioprinting, and Others (Stereolithography, Fused Deposition Modelling, etc.). Among them, Inkjet Bioprinting acquired a significant share of the Global 3D Bioprinting market, owing to their amplifying usage in the regeneration of cartilage tissues & skin cells.
Further, their high printing speed, along with their efficacy to directly deposit cells & biomaterials over skin & cartilage, enhances their adoption in the clinical sector. Also, the non-contact nature of inkjet techniques is projected to expand its demand during 2023-2028, owing to its ability to reduce the chances of contamination in the laboratories.
North America Acquires the Major Share of the Market
Geographically, North America has witnessed considerable growth during 2018-2022, owing to the amplifying investment by private companies & government research centers for the technological advancement of 3D bioprinting technology. This high investment is primarily intended to reduce the use of animal models for testing drugs & cosmetics and boost the use of 3D-printed tissues instead. Further, the presence of major market players in the region, who are continuously expanding their product offerings through improving technology, supports the market growth in the region.
With strategic initiatives, such as mergers, collaborations, and acquisitions, the leading market players, including Cellink, 3D Systems Corporation, Regemat 3D, Aspect Biosystems Ltd, Cyfuse Biomedical KK, Envision TEC GmbH, RegenHU SA, GeSIM GmbH, Inventia Life Science PTY LTD, Vivax Bio, Poietis, Advanced Solutions Life Sciences, LLC, Collplant Biotechnologies Ltd., Regenovo Biotechnology Co. Ltd., and Others, are looking forward to strengthening their market position.
Key Questions Answered in the Research Report